Short-term Supplementation, Bone Turnover and Antioxidant Status in Menopause

Short-term Supplementation, Bone Turnover and Antioxidant Status in Postmenopausal Stage: A Placebo Controlled Study.

This is a 8-week, double-blinded, placebo-controlled, randomized intervention trial to investigate the effects of Mg and Zn supplementation on antioxidant status and bone hormonal parameters. Participants were randomly assigned to one of three treatment groups: Placebo group (PbG: 25 women); Magnesium Group - 500 mg/day of Mg (MgG: 27 women); Zinc Group - 50 mg/day of Zn (ZnG: 26 women).

Seventy-eight healthy postmenopausal volunteers aged between 44 and 76 were recruited once had been informed about the protocol. This is a 8-week, double-blinded, placebo-controlled, randomized intervention trial to investigate the effects of Mg and Zn supplementation on antioxidant status and bone hormonal parameters. Participants were randomly assigned to one of three treatment groups: Placebo group (PbG: 25 women); Magnesium Group - 500 mg/day of Mg (MgG: 27 women); Zinc Group - 50 mg/day of Zn (ZnG: 26 women).

Inclusion Criteria:

• to present postmenopausal status (with at least 12 months of amenorrhea)
• to present low status in Mg and/or Zn obtained in a previous biochemical assessment
• not present any pathology that could affect their nutritional status
• not to be subjected to hormone replacement therapy (HRT)
• not to demonstrate lactose intolerance

Exclusion criteria

• acute or terminal illness
• unwillingness to either complete the study requirements or to be randomised into control or experimental group
• to be smoker
• to be on a medication regimen